Skip to Content
Looking to save on your medications?  Find out how 

3 Interactions found for:

clonidine
Interactions Summary
  • 2 Major
  • 1 Moderate
  • 0 Minor
  • clonidine

Drug Interactions

A total of 394 medications are known to interact with clonidine. Add another medication to view potential interactions with this medication.

Drug and Food Interactions

Moderate
Clonidine + Food

The following applies to the ingredients: Clonidine

MONITOR: Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and/or agents with hypotensive properties, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.

MANAGEMENT: Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia. Patients should also avoid driving or operating hazardous machinery until they know how the medications affect them.

References

  1. Sternbach H "Fluoxetine-associated potentiation of calcium-channel blockers." J Clin Psychopharmacol 11 (1991): 390-1
  2. Shook TL, Kirshenbaum JM, Hundley RF, Shorey JM, Lamas GA "Ethanol intoxication complicating intravenous nitroglycerin therapy." Ann Intern Med 101 (1984): 498-9
  3. Feder R "Bradycardia and syncope induced by fluoxetine." J Clin Psychiatry 52 (1991): 139
  4. Ellison JM, Milofsky JE, Ely E "Fluoxetine-induced bradycardia and syncope in two patients." J Clin Psychiatry 51 (1990): 385-6
  5. Rodriguez de la Torre B, Dreher J, Malevany I, et al. "Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients." Ther Drug Monit 23 (2001): 435-40
  6. Cerner Multum, Inc. "Australian Product Information." O 0
  7. Pacher P, Kecskemeti V "Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns?" Curr Pharm Des 10 (2004): 2463-75
  8. Andrews C, Pinner G "Postural hypotension induced by paroxetine." BMJ 316 (1998): 595
  9. "Product Information. Buprenorphine (buprenorphine)." G.L. Pharma UK Ltd (2023):
  10. "Product Information. Temgesic (buprenorphine)." Reckitt Benckiser Pty Ltd (2023):

Drug and Pregnancy Interactions

The following applies to the ingredients: Clonidine

This drug should be used during pregnancy only if the benefit outweighs the risk.

AU TGA pregnancy category: B3
US FDA pregnancy category:
-Oral tablets: C
-Extended-release oral suspension, injection for infusion, transdermal patch: Not assigned

Risk summary: No data are available on the use of this drug in pregnant women to inform a drug-related risk.

Comments:
-A pregnancy exposure registry is available.
-If this drug is used during pregnancy careful monitoring of mother and child is recommended.

Animal studies have failed to reveal evidence of teratogenicity although an increased incidence of fetal resorption has been demonstrated. There are limited controlled data in human pregnancy. This drug passes the placental barrier and may lower the heart rate of the fetus. A transient rise in blood pressure in the newborn cannot be excluded postpartum.

To monitor the outcomes of pregnant women exposed to this drug, a pregnancy registry has been established. Physicians are encouraged to register patients and pregnant women are encouraged to register themselves by calling 1-866-961-2388.

AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans.

US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. "Product Information. CloNIDine Hydrochloride (clonidine)." Unichem Pharmaceuticals Inc (2016):
  4. "Product Information. CloNIDine Hydrochloride (cloNIDine)." Alembic Pharmaceuticals (2021):
  5. "Product Information. Catapres-TTS-1 (cloNIDine)." Boehringer Ingelheim (2023):
  6. "Product Information. Duraclon (cloNIDine)." Mylan Institutional (formally Bioniche Pharma USA Inc) (2021):
  7. "Product Information. Nexiclon XR (cloNIDine)." Athena Bioscience, LLC. (2021):
  8. "Product Information. Onyda XR (cloNIDine)." Tris Pharma Inc (2025):

Drug and Breastfeeding Interactions

The following applies to the ingredients: Clonidine

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.

Excreted into human milk: Yes

Comments:
-Concentrations of this drug in human breast milk are approximately twice those found in maternal plasma.
-Other drugs may be preferred, especially while nursing a newborn or preterm infant, due to possible infant side effects and negative effects on lactation.

References

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. United States National Library of Medicine "Toxnet. Toxicology Data Network. http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT" (2013):
  4. "Product Information. CloNIDine Hydrochloride (clonidine)." Unichem Pharmaceuticals Inc (2016):

Therapeutic Duplication Warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

Switch to: Consumer Interactions

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Disclaimer: This content should not be considered complete and should not be used in place of a call or visit to a healthcare professional. Use of this content is subject to our terms of use & medical disclaimer.